PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Financial Statements and Exhibits

PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.

Exhibit No. Description
99.1 Press release, dated November 28, 2017
Story continues below


PHASERX, INC. Exhibit
EX-99.1 2 tv480310_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency   SEATTLE,…
To view the full exhibit click here

About PhaseRx, Inc. (NASDAQ:PZRX)

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

An ad to help with our costs